Advertisement

Russian Chemical Bulletin

, Volume 67, Issue 10, pp 1781–1793 | Cite as

Vaccines for substance abuse treatment: new approaches in the immunotherapy of addictions

  • M. A. Myagkova
  • V. S. Morozova
Article
  • 7 Downloads

Abstract

Addictions associated with the use of physoactive substances pose a serious threat for both patients and society and continue to be a serious medical social problem worlwide. A high recurrence rate makes especially topical the search for new approaches to the treatment and primary prevention of these diseases. The development of immunological and pharmacotherapeutic methods is a promising trend in the therapy of addictions. Immunization against diseased addiction or immunoprophylaxis are of practical significance to prevent futher recurrences and can be an efficient medical tool to eradicate dependence diseases. The review describes advances in the vaccine therapy of psychoactive substance abuse (drug abuse, tobacco smoking, and alcoholism), including preclinical and clinical trials of these medicines. New strategies to enhance the specific immune response by changing the structure of conjugated immunogen and adjuvant molecules are considered. The difficulties faced by the developers in clinical trials of vaccines are analyzed and new approaches to increase the therapeutic efficacy are reviewed.

Key words

drug addiction substance abuse alcoholism smoking psychoactive substances vaccine immunogen anti-drug vaccines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    U. S. Department of Justice, Drug Enforcement Administration, National Drug Threat Assessment Summary, 2015; https://www.dea.gov/docs/2015%20NDTA%20Report.pdf.
  2. 2.
    Stenogramma vystupleniya ministra vnutrennikh del RF V. A. Kolokol´tseva v Sovete Federatsii 28 marta 2108 g. [Shorthand record of the speech of the Minister of Internal Affairs of the Russian Federation V. A. Kolokol´tsev in the Council of Federation on March 28, 2018]; http://www.council.gov.ru/activity/meetings/90693/transcript/(in Russian).
  3. 3.
    Osnovnye pokazateli deyatel´nosti narkologicheskoi sluzhby Rossiiskoi Federatsii v 2015–2016 gg.: statisticheskii sbornik [Main activity indices of the Narcological Service of the Russian Federation in 2015–2016: statistics digest], National Research Center of Narcology, Branch of the Serbsky Federal Medical Research Center of Psychiatry and Narcology, Ministry of Health of the Russian Federation, Moscow, 2017, 183 pp. (in Russian).Google Scholar
  4. 4.
    G. E. Woody, Curr. Psychiatry Rep., 2014, 16,489.CrossRefGoogle Scholar
  5. 5.
    R. D. Heekin, D. Shorter, T. R. Kosten, Expert. Rev. Vaccines, 2017, 16, 1067.CrossRefGoogle Scholar
  6. 6.
    G. N. Stowe, J. E. Schlosburg, L. F. Vendruscolo, S. Edwards, K. K. Misra, G. Schulteis, J. S. Zakhari, G. F. Koob, K. D. Janda, CNS Neurol. Disord. Drug Targets, 2011, 10,865.CrossRefGoogle Scholar
  7. 7.
    M. Pravetoni, M. Le Naour, T. Harmon, A. Tucker, P. S. Portoghese, P. R. Pentel, J. Pharmacol. Exp. Ther., 2012, 341,225.CrossRefGoogle Scholar
  8. 8.
    T. A. Kosten, X. Y. Shen, P. W. O´Malley, B. M. Kinsey, E. D. Lykissa, F. M. Orson, T. R. Kosten, Prog. Neuro psychopharmacol. Biol. Psychiatry, 2013, 45,223.CrossRefGoogle Scholar
  9. 9.
    C. R. Alving, G. R. Matyas, O. Torres, R. Jalah, Z. Beck, Vaccine, 2014, 32, 5382.CrossRefGoogle Scholar
  10. 10.
    M. Haney, E. W. Gunderson, H. Jiang, E. D. Collins, R. W. Foltin, Biol. Psychiatry, 2010, 67,59.CrossRefGoogle Scholar
  11. 11.
    X. Cai, T. Whitfield, A. Y. Moreno, Y. Grant, M. S. Hixon, G. F. Koob, K. D. Janda, Mol. Pharm., 2013, 10, 4176.CrossRefGoogle Scholar
  12. 12.
    J. W. Lockner, J. M. Lively, K. C. Collins, J. C. Vendruscolo, M. R. Azar, K. D. Janda, J. Med. Chem., 2015, 58, 1005.CrossRefGoogle Scholar
  13. 13.
    X. Cai, K. Tsuchikama, K. D. Janda, J. Am. Chem. Soc., 2013, 135, 2971.CrossRefGoogle Scholar
  14. 14.
    K. C. Collins, K. D. Janda, Bioconjug. Chem., 2014, 25,593.CrossRefGoogle Scholar
  15. 15.
    A. Y. Moreno, A. V. Mayorov, K. D. Janda, J. Am. Chem. Soc., 2011, 133, 6587.CrossRefGoogle Scholar
  16. 16.
    G. R. Matyas, K. C. Rice, K. Cheng, F. Li, J. F. Antoline, M. R. Iyer, A. E. Jacobson, A. V. Mayorov, Z. Beck, O. B. Torres, C. R. Alving, Vaccine, 2014, 32, 1473.CrossRefGoogle Scholar
  17. 17.
    R. Jalah, O. B. Torres, A. V. Mayorov, F. Li, J. F. Antoline, A. E. Jacobson, K. C. Rice, J. R. Deschamps, Z. Beck, C. R. Alving, G. R. Matyas, Bioconjug. Chem., 2015, 26, 1041.CrossRefGoogle Scholar
  18. 18.
    M. D. Raleigh, P. R. Pentel, M. G. LeSage, PLoS One, 2014, 9, e115696.CrossRefGoogle Scholar
  19. 19.
    F. Li, K. Cheng, J. F. Antoline, M. R. Iyer, G. R. Matyas, O. B. Torres, R. Jalah, Z. Beck, C. R. Alving, D. A. Parrish, J. R. Deschamps, A. E. Jacobson, K. C. Rice, Org. Biomol. Chem., 2014, 12, 7211.CrossRefGoogle Scholar
  20. 20.
    J. E. Schlosburg, L. F. Vendruscolo, P. T. Bremer, J. W. Lockner, C. L. Wade, A. A. Nunes, G. N. Stowe, S. Edwards, K. D. Janda, G. F. Koob, Proc. Natl. Acad. Sci. USA, 2013, 110, 9036.CrossRefGoogle Scholar
  21. 21.
    G. N. Stowe, L. F. Vendruscolo, S. Edwards, J. E. Schlosburg, K. K. Misra, G. Schulteis, A. V. Mayorov, J. S. Zakhari, G. F. Koob, K. D. Janda, J. Med. Chem., 2011, 54, 5195.CrossRefGoogle Scholar
  22. 22.
    S. Gross, J. Grant, R. Wong, R. Schuster, P. Lomax, D. Campbell, Immunochem., 1974, 11,453.CrossRefGoogle Scholar
  23. 23.
    M. Pravetoni, M. Le Naour, A. M. Tucker, T. M. Harmon, T. M. Hawley, P. S. Portoghese, P. R. Pentel, J. Med. Chem., 2013, 56,915.CrossRefGoogle Scholar
  24. 24.
    M. D. Raleigh, S. J. Peterson, M. Laudenbach, F. Baruffaldi, F. I. Carroll, S. D. Comer, H. A. Navarro, T. L. Langston, S. P. Runyon, S. Winston, M. Pravetoni, P. R. Pentel, PLoS One, 2017, 12, e0184876.CrossRefGoogle Scholar
  25. 25.
    F. I. Carroll, B. E. Blough, R. R. Pidaparthi, P. Abraham, P. K. Gong, L. Deng, X. Huang, M. Gunnell, J. O. Lay, E. C. Peterson, S. M. Owens, J. Med. Chem., 2011, 54, 5221.CrossRefGoogle Scholar
  26. 26.
    M. Pravetoni, D. E. Keyler, R. R. Pidaparthi, F. I. Carroll, S. P. Runyon, M. P. Murtaugh, C. A. Earley, P. R. Pentel, Biochem. Pharmacol., 2012, 83,543.CrossRefGoogle Scholar
  27. 27.
    D. C. Pryde, L. H. Jones, D. P. Gervais, D. R. Stead, D. C. Blakemore, M. D. Selby, A. D. Brown, J. W. Coe, M. Badland, D. M. Beal, R. Glen, Y. Wharton, G. J. Miller, P. White, N. Zhang, M. Benoit, K. Robertson, J. R. Merson, H. L. Davis, M. J. McCluskie, PLoS One, 2013, 8, e76557.CrossRefGoogle Scholar
  28. 28.
    M. J. McCluskie, D. C. Pryde, D. P. Gervais, D. R. Stead, N. Zhang, M. Benoit, K. Robertson, I. J. Kim, T. Tharmanathan, J. R. Merson, H. L. Davis, Int. Immunopharmacol., 2013, 16,50.CrossRefGoogle Scholar
  29. 29.
    M. J. McCluskie, J. Thorn, P. R. Mehelic, P. Kolhe, K. Bhatta charya, J. I. Finneman, D. R. Stead, M. B. Piatchek, N. Zhang, G. Chikh, J. Cartier, D. M. Evans, J. R. Merson, H. L. Davis, Int. Immunopharmacol., 2015, 25,518.CrossRefGoogle Scholar
  30. 30.
    B. Anton, A. Salazar, A. Flores, M. Matus, R. Marin, J. A. Hernandez, P. Leff, Hum. Vaccines, 2009, 5,214.CrossRefGoogle Scholar
  31. 31.
    J. E. Schlosburg, L. F. Vendruscolo, P. T. Bremer, J. W. Lockner, C. L. Wade, A. A. Nunes, G. N. Stowe, S. Edwards, K. D. Janda, G. F. Koob, Proc. Natl. Acad. Sci. USA, 2013, 110, 9036.CrossRefGoogle Scholar
  32. 32.
    G. R. Matyas, A. V. Mayorov, K. C. Rice, A. E. Jacobson, K. Cheng, M. R. Iyer, F. Li, Z. Beck, K. D. Janda, C. R. Alving, Vaccine, 2013, 31, 2804.CrossRefGoogle Scholar
  33. 33.
    S. D. Sanderson, S. R. Cheruku, M. P. Padmanilayam, J. L. Vennerstrom, G. M. Thiele, M. I. Palmatier, R. A. Bevins, Int. Immunopharmacol., 2003, 3,137.CrossRefGoogle Scholar
  34. 34.
    M. J. Duryee, R. A. Bevins, C. M. Reichel, J. E. Murray, Y. Dong, G. M. Thiele, S. D. Sanderson, Vaccine, 2009, 27, 2981.CrossRefGoogle Scholar
  35. 35.
    J. W. Lockner, L. M. Eubanks, J. L. Choi, J. M. Lively, J. E. Schlosburg, K. C. Collins, D. Globisch, R. J. Rosenfeld-Gunn, I. A. Wilson, K. D. Janda, Mol. Pharm., 2015, 12,653.CrossRefGoogle Scholar
  36. 36.
    K. D. Miller, R. Roque, C. H. Clegg, PLoS One, 2014, 9, e114366.CrossRefGoogle Scholar
  37. 37.
    A. Maoz, M. J. Hicks, S. Vallabhjosula, M. Synan, P. J. Kothari, J. P. Dyke, D. J. Ballon, S. M. Kaminsky, B. P. De, J. B. Rosenberg, D. Martinez, G. F. Koob, K. D. Janda, R. G. Crystal, Neuropsychopharmacology, 2013, 38, 2170.CrossRefGoogle Scholar
  38. 38.
    J. Rosenberg, B. De, M. Hicks, K. Janda, S. Kaminsky, S. Worgall, R. Crystal, Hum. Gene Ther., 2013, 24,595.CrossRefGoogle Scholar
  39. 39.
    M. J. Hicks, S. M. Kaminsky, B. P. De, J. B. Rosenberg, S. M. Evans, R. W. Foltin, D. M. Andrenyak, D. E. Moody, G. F. Koob, K. D. Janda, R. J. Ricart Arbona, M. Lepherd, R. G. Crystal, Hum. Gene Ther. Clin. Dev., 2014, 25,40.CrossRefGoogle Scholar
  40. 40.
    G. Koob, M. J. Hicks, S. Wee, J. B. Rosenberg, B. P. De, S. M. Kaminsky, A. Moreno, K. D. Janda, R. G. Crystal, CNS Neurol. Disord. Drug Targets, 2011, 10,899.CrossRefGoogle Scholar
  41. 41.
    Q. Q. Li, C. Y. Sun, Y. X. Luo, Y. X. Xue, S. Q. Meng, L. Z. Xu, N. Chen, J. H. Deng, H. F. Zhai, T. R. Kosten, J. Shi, L. Lu, H. Q. Sun, Int. J. Neuropsychopharmacol., 2014, 18, pyu093.CrossRefGoogle Scholar
  42. 42.
    M. J. Hicks, S. M. Kaminsky, B. P. De, J. B. Rosenberg, S. M. Evans, R. W. Foltin, D. M. Andrenyak, D. E. Moody, G. F. Koob, K. D. Janda, R. J. RicartArbona, M. L. Lepherd, R. G. Crystal, Hum. Gene Ther. Clin. Dev., 2014, 25,40.CrossRefGoogle Scholar
  43. 43.
    RF Pat. 2236257; Byull. Isobret. [Invention Bull.], 2004 (in Russian).Google Scholar
  44. 44.
    V. S. Morozova, S. N. Petrochenko, M. A. Myagkova, Russ. Chem. Bull., 2017, 66, 1925.CrossRefGoogle Scholar
  45. 45.
    M. Pravetoni, J. S. Vervacke, M. D. Distefano, A. M. Tucker, M. Laudenbach, P. R. Pentel, PLoS One, 2014, 9, e96547.CrossRefGoogle Scholar
  46. 46.
    M. Laudenbach, F. Baruffaldi, J. S. Vervacke, M. D. Distefano, P. J. Titcombe, D. L. Mueller, N. J. Tubo, T. S. Griffith, M. Pravetoni, J. Immunol., 2015, 194, 5926.CrossRefGoogle Scholar
  47. 47.
    M. J. McCluskie, J. Thorn, D. P. Gervais, D. R. Stead, N. Zhang, M. Benoit, J. Cartier, I. J. Kim, K. Bhattacharya, J. I. Finneman, J. R. Merson, H. L. Davis, Int. Immunopharm acol., 2015, 29,663.CrossRefGoogle Scholar
  48. 48.
    J. J. Moon, B. Huang, D. J. Irvine, Adv. Mater., 2012, 24, 3724.CrossRefGoogle Scholar
  49. 49.
    D. J. Irvine, M. C. Hanson, K. Rakhra, T. Tokatlian, Chem. Rev., 2015, 115, 11109.CrossRefGoogle Scholar
  50. 50.
    S. Jain, D. T. O´Hagan, M. Singh, Expert. Rev. Vaccines, 2011, 10, 1731.CrossRefGoogle Scholar
  51. 51.
    M. Braun, C. Jandus, P. Maurer, A. Hammann-Haenni, K. Schwarz, M. F. Bachmann, D. E. Speiser, P. Romero, Eur. J. Immunol, 42,330.Google Scholar
  52. 52.
    F. Zabel, D. Mohanan, J. Bessa, A. Link, A. Fettelschoss, P. Saudan, T. M. Kundig, M. F. Bachmann, J. Immunol., 2014, 192, 5499.CrossRefGoogle Scholar
  53. 53.
    J. Cornuz, S. Zwahlen, W. F. Jungi, J. Osterwalder, K. Klingler, G. van Melle, Y. Bangala, I. Guessous, P. Muller, J. Willers, P. Maurer, M. F. Bachmann, T. Cerny, PLoS One, 2008, 3, e2547.CrossRefGoogle Scholar
  54. 54.
    K. C. Collins, J. E. Schlosburg, J. W. Lockner, P. T. Bremer, B. A. Ellis, K. D. Janda, Chem. Commun. (Camb.), 2014, 50, 4079.CrossRefGoogle Scholar
  55. 55.
    J. W. Lockner, S. O. Ho, K. C. McCague, S. M. Chiang, T. Q. Do, G. Fujii, K. D. Janda, Bioorg. Med. Chem. Lett., 2013, 23,975.CrossRefGoogle Scholar
  56. 56.
    Y. Hu, H. Zheng, W. Huang, C. Zhang, Hum. Vaccin. Immunother., 2014, 10,64.CrossRefGoogle Scholar
  57. 57.
    H. Zheng, Y. Hu, W. Huang, S. de Villiers, P. Pentel, J. Zhang, H. Dorn, M. Ehrich, C. Zhang, J. Biomed. Nanotechnol., 2015, 11, 2197.CrossRefGoogle Scholar
  58. 58.
    A. A. Ivanov, A. A. Babayants, Y. B. Deshevoi, N. I. Il´ina, V. N. Mal´tsev, B. V. Rogo zhin, D. V. Pinegin, A. M. Ulanova, Immunologia [Immunology], 2008, 29, 278 (in Russian).Google Scholar
  59. 59.
    B. S. Powell, A. K. Andrianov, P. C. Fusco, Clin. Exp. Vaccine Res., 2015, 4,23.CrossRefGoogle Scholar
  60. 60.
    Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers, Selecta Biosciences, Inc.; https://clinicaltrials.gov/ct2/show/NCT01478893.
  61. 61.
    R. I. Desai, J. Bergman, Neuropsychopharmacology, 2016, 41,377.CrossRefGoogle Scholar
  62. 62.
    P. O. Ilyinskii, C. J. Roy, C. P. O´Neil, E. A. Browning, L. A. Pittet, D. H. Altreuter, F. Alexis, E. Tonti, J. Shi, P. A. Basto, M. Iannacone, A. F. Radovic-Moreno, R. S. Langer, O. C. Farokhzad, U. H. von Andrian, L. P. Johnston, T. K. Kishimoto, Vaccine, 2014, 32, 2882.CrossRefGoogle Scholar
  63. 63.
    X. Liu, Y. Xu, T. Yu, C. Clifford, Y. Liu, H. Yan, Y. Chang, Nano Lett., 2012, 12, 4254.CrossRefGoogle Scholar
  64. 64.
    J. S. Rudra, S. Mishra, A. S. Chong, R. A. Mitchell, E. H. Nardin, V. Nussenzweig, J. H. Collier, Biomaterials, 2012, 33, 6476.CrossRefGoogle Scholar
  65. 65.
    P. Stavropoulos, F. N. Papavasiliou, J. Immunol. Methods, 2010, 362,190.CrossRefGoogle Scholar
  66. 66.
    M. F. Bachmann, G. T. Jennings, Nat. Rev. Immunol., 2010, 10,787.CrossRefGoogle Scholar
  67. 67.
    D. J. Irvine, M. A. Swartz, G. L. Szeto, Nat. Mater., 2013, 12,978.CrossRefGoogle Scholar
  68. 68.
    M. Pravetoni, M. D. Raleigh, M. Le Naour, A. M. Tucker, T. M. Harmon, J. M. Jones, A. K. Birnbaum, P. S. Portoghese, P. R. Pentel, Vaccine, 2012, 30, 4617.CrossRefGoogle Scholar
  69. 69.
    A. B. Norman, M. K. Norman, W. R. Buesing, M. R. Tabet, V. L. Tsibulsky, W. J. Ball, J. Pharmacol. Exp. Ther., 2009, 328,873.CrossRefGoogle Scholar
  70. 70.
    D. E. Keyler, S. A. Roiko, E. Benlhabib, M. G. LeSage, J. V. St Peter, S. Stewart, S. Fuller, C. T. Le, P. R. Pentel, Drug Metab. Dispos., 2005, 33, 1056.CrossRefGoogle Scholar
  71. 71.
    J. S. Hardin, W. D. Wessinger, G. R. Wenger, J. W. Proksch, E. M. Laurenzana, S. M. Owens, J. Pharmacol. Exp. Ther., 2002, 302,119.CrossRefGoogle Scholar
  72. 72.
    W. B. Gentry, E. M. Laurenzana, D. K. Williams, J. R. West, R. J. Berg, T. Terlea, S. M. Owens, Int. Immunopharmacol., 2006, 6,968.CrossRefGoogle Scholar
  73. 73.
    A. M. Kvello, J. M. Andersen, E. L. Oiestad, J. Morland, I. L. Bogen, J. Pharmacol. Exp. Ther., 2016, 358,181.CrossRefGoogle Scholar
  74. 74.
    N. Nanaware-Kharade, S. Thakkar, G. A. Gonzalez, 3rd, E. C. Peterson, Sci. Rep., 2015, 5, 12060.CrossRefGoogle Scholar
  75. 75.
    D. Corti, A. Lanzavecchia, Microbiol. Spectr., 2014, 2,5.Google Scholar
  76. 76.
    R. R. Beerli, M. Bauer, R. B. Buser, M. Gwerder, S. Muntwiler, P. Maurer, P. Saudan, M. F. Bachmann, Proc. Natl. Acad. Sci. USA, 2008, 105, 14336.CrossRefGoogle Scholar
  77. 77.
    M. G. LeSage, D. Shelley, M. Pravetoni, P. R. Pentel, Pharmacol. Biochem. Behav., 2012, 102,157.CrossRefGoogle Scholar
  78. 78.
    M. D. Hambuchen, F. I. Carroll, D. Ruedi-Bettschen, H. P. Hendrickson, L. J. Hennings, B. E. Blough, L. E. Brieaddy, R. R. Pidaparthi, S. M. Owens, J. Med. Chem., 2015, 58, 4665.CrossRefGoogle Scholar
  79. 79.
    S. K. Sudakov, I. V. Rusakova, Byull. Eksp. Biol. [Bull. Exp. Biol.], 2005, 140, 535 (in Russian).CrossRefGoogle Scholar
  80. 80.
    A. G. Berezina, N. B. Gamaleya, L. I. Ul´yanova, K. A. Shestakov, M. A. Ul´yanova, G. D. Kapanadze, N. V. Stankova, A. O. Revyakin, Yu. V. Fokin, G. I. Krotov, G. M. Rodchenkov, Narkologiya [Narcology], 2015, 11, 25 (in Russian).Google Scholar
  81. 81.
    D. W. Landry, K. Zhao, G. X. Yang, M. Glickman, T. M. Georgiadis, Science, 1993, 259, 1899.CrossRefGoogle Scholar
  82. 82.
    F. Zheng, C. G. Zhan, Org. Biomol. Chem., 2008, 6,836.CrossRefGoogle Scholar
  83. 83.
    Y. Xu, M. S. Hixon, N. Yamamoto, L. A. McAllister, A. D. Wentworth, P. Wentworth, Jr, K. D. Janda, Proc. Natl. Acad. Sci. USA, 2007, 104, 3681.CrossRefGoogle Scholar
  84. 84.
    T. J. Dickerson, N. Yamamoto, K. D. Janda, Bioorg. Med. Chem., 2004, 12, 4981.CrossRefGoogle Scholar
  85. 85.
    S. Brimijoin, F. Orson, T. R. Kosten, B. Kinsey, X. Y. Shen, S. J. White, Y. Gao, Chem. Biol. Interact., 2013, 203,212.CrossRefGoogle Scholar
  86. 86.
    S. Xue, J. E. Schlosburg, K. D. Janda, J. Am. Chem. Soc., 2015, 137, 10136.CrossRefGoogle Scholar
  87. 87.
    X. Chen, L. Xue, S. Hou, Z. Jin, T. Zhang, F. Zheng, C. G. Zhan, Proc. Natl. Acad. Sci. USA, 2016, 113,422.CrossRefGoogle Scholar
  88. 88.
    M. J. Hicks, J. B. Rosenberg, B. P. De, O. E. Pagovich, C. N. Young, J. P. Qiu, S. M. Kaminsky, N. R. Hackett, S. Worgall, K. D. Janda, R. L. Davisson, R. G. Crystal, Sci. Transl. Med., 2012, 4, 140ra187.CrossRefGoogle Scholar
  89. 89.
    J. B. Rosenberg, M. J. Hicks, B. P. De, O. Pagovich, E. Frenk, K. D. Janda, S. Wee, G. F. Koob, N. R. Hackett, S. M. Kaminsky, S. Worgall, N. Tignor, J. G. Mezey, R. G. Crystal, Hum. Gene Ther., 2012, 23,451.CrossRefGoogle Scholar
  90. 90.
    S. Brimijoin, CNS Neurol. Disord. Drug Targets, 2011, 10,880.CrossRefGoogle Scholar
  91. 91.
    M. E. Carroll, N. E. Zlebnik, J. J. Anker, T. R. Kosten, F. M. Orson, X. Shen, B. Kinsey, R. J. Parks, Y. Gao, S. Brimijoin, PLoS One, 2012, 7, e43536.CrossRefGoogle Scholar
  92. 92.
    J. R. Smethells, N. Swalve, S. Brimijoin, Y. Gao, R. J. Parks, A. Greer, M. E. Carroll, J. Pharmacol. Exp. Ther., 2016, 357,375.CrossRefGoogle Scholar
  93. 93.
    V. Murthy, S. Reyes, L. Geng, Y. Gao, S. Brimijoin, J. Pharmacol. Exp. Ther., 2016, 356,720.CrossRefGoogle Scholar
  94. 94.
    J. Liu, A. R. Yang, T. Kelly, A. Puche, C. Esoga, H. L. June, Jr, A. Elnabawi, I. Merchenthaler, W. Sieghart, H. L. June, Sr, L. Aurelian, Proc. Natl. Acad. Sci. USA, 2011, 108, 4465.CrossRefGoogle Scholar
  95. 95.
    V. V. Pavshintsev, N. A. Mit´kin, E. A. Kushnir, O. A. Averina, M. L. Lovat´, Tekhnologii zhivykh system [Living System Technologies], 2016, 13, No. 4, 41 (in Russian).Google Scholar
  96. 96.
    V. V. Pavshintsev, N. A. Mitkin, O. Y. Frolova, E. A. Kushnir, O. A. Averina, M. L. Lovat, Physiol. Behav., 2017, 179,458.CrossRefGoogle Scholar
  97. 97.
    A. C. Sanchez, C. Li, B. Andrews, J. A. Asenjo, R. J. Samulski, Hum. Gene Ther., 28,717.Google Scholar
  98. 98.
    M. Pravetoni, Hum. Vaccin. Immunother., 2016, 12, 3005.CrossRefGoogle Scholar
  99. 99.
    D. K. Hatsukami, D. E. Jorenby, D. Gonzales, N. A. Rigotti, E. D. Glover, C. A. Oncken, D. P. Tashkin, V. I. Reus, R. C. Akhavain, R. E. Fahim, P. D. Kessler, M. Niknian, M. W. Kalnik, S. I. Rennard, Clin. Pharmacol. Ther., 2011, 89,392.CrossRefGoogle Scholar
  100. 100.
    B. A. Martell, F. M. Orson, J. Poling, E. Mitchell, R. D. Rossen, T. Gardner, T. R. Kosten, Arch. Gen. Psychiatry, 2009, 66, 1116.CrossRefGoogle Scholar
  101. 101.
    R. E. Fahim, P. D. Kessler, M. W. Kalnik, Expert. Rev. Vaccines, 2013, 12,333.CrossRefGoogle Scholar
  102. 102.
    P. H. Hoogsteder, D. Kotz, P. I. van Spiegel, W. Viechtbauer, O. C. van Schayck, Addiction, 2014, 109, 1252.CrossRefGoogle Scholar
  103. 103.
    P. H. Hoogsteder, D. Kotz, P. I. van Spiegel, W. Viechtbauer, R. Brauer, P. D. Kessler, M. W. Kalnik, R. E. Fahim, O. C. van Schayck, BMC Public Health, 2012, 12, 1052.CrossRefGoogle Scholar
  104. 104.
    A Fmri Study on the Effects of a Conjugate Vaccine and Placebo on CNS Activation and Behavior Following a Nicotine Challenge (EPU057), Maastricht University Medical Center; https://clinicaltrials.gov/ct2/show/NCT01318668.
  105. 105.
    I. Esterlis, J. O. Hannestad, E. Perkins, F. Bois, D. C. D´Souza, R. F. Tyndale, J. P. Seibyl, D. M. Hatsukami, K. P. Cosgrove, S. S. O´Malley, Am. J. Psychiatry, 2013, 170,399.CrossRefGoogle Scholar
  106. 106.
    A. Mukhin, Improving the Efficacy of Anti-Nicotine Immunotherapy (PETNic002); https://clinicaltrials.gov/ct2/show/NCT01280968.
  107. 107.
    Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking, Novartis; https://clinicaltrials.gov/ct2/show/NCT00736047.
  108. 108.
    Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers, Cytos Biotechnology AG; https://clinicaltrials.gov/ct2/show/NCT00369616.
  109. 109.
    S. Tonstad, E. Heggen, H. Giljam, P. A. Lagerback, P. Tonnesen, L. D. Wikingsson, N. Lindblom, S. de Villiers, T. H. Svensson, K. O. Fagerstrom, Nicotine Tob. Res., 2013, 15, 1492.CrossRefGoogle Scholar
  110. 110.
    Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation, Celtic Pharma Development Services; https://clinicaltrials.gov/ct2/show/NCT00633321.
  111. 111.
    Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals, Weill Medical College of Cornell University; https://clinicaltrials.gov/ct2/show/NCT02455479.
  112. 112.
    Safety Study of Ch-mAb7F9 for Methamphetamine Abuse, InterveXion Therapeutics, LLC; https://clinicaltrials.gov/ct2/show/NCT01603147.
  113. 113.
    A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers, Pfizer; https://clinicaltrials.gov/ct2/show/NCT0167264.5.
  114. 114.
    M. R. Carrera, J. A. Ashley, T. Z. Hoffman, S. Isomura, P. Wirsching, G. F. Koob, K. D. Janda, Bioorg. Med. Chem., 2004, 12,563.CrossRefGoogle Scholar
  115. 115.
    M. R. Carrera, J. A. Ashley, B. Zhou, P. Wirsching, G. F. Koob, K. D. Janda, Proc. Natl. Acad. Sci. USA, 2000, 97, 6202.CrossRefGoogle Scholar
  116. 116.
    I. L. Bogen, F. Boix, E. Nerem, J. Morland, J. M. Andersen, J. Pharmacol. Exp. Ther., 2014, 349,568.CrossRefGoogle Scholar
  117. 117.
    M. W. Stevens, R. L. Henry, S. M. Owens, R. Schutz, W. B. Gentry, MAbs, 2014, 6, 1649.CrossRefGoogle Scholar
  118. 118.
    T. L. Kirley, A. B. Norman, Hum. Vaccin. Immunother., 2015, 11,458.CrossRefGoogle Scholar
  119. 119.
    O. Cohen-Barak, J. Wildeman, J. van de Wetering, J. Hettinga, P. Schuilenga-Hut, A. Gross, S. Clark, M. Bassan, Y. Gilgun-Sherki, B. Mendzelevski, O. Spiegelstein, J. Clin. Pharmacol., 2015, 55,573.CrossRefGoogle Scholar
  120. 120.
    A. F. Nasser, P. J. Fudala, B. Zheng, Y. Liu, C. Heidbreder, J. Addict. Dis., 2014, 33,289.CrossRefGoogle Scholar
  121. 121.
    M. J. Shram, O. Cohen-Barak, B. Chakraborty, M. Bassan, K. A. Schoedel, H. Hallak, E. Eyal, S. Weiss, Y. Gilgun, E. M. Sellers, J. Faulknor, O. Spiegelstein, J. Clin. Psychopharmacol., 2015, 35,396.CrossRefGoogle Scholar
  122. 122.
    P. Skolnick, Trends Pharmacol. Sci., 2015, 36, 628.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of Physiologically Active CompoundsRussian Academy of SciencesChernogolovka, Moscow RegionRussian Federation

Personalised recommendations